Abstract：Objective：To observe the effect of Guanxinning on transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) in serum in patients with diastolic heart failure (DHF) of coronary heart disease. Methods： A total of 100 cases of DHF patients were selected and divided into the routine group and the treatment group according to the random number table method， with 50 patients in each group. The routine group was given basic treatment like strengthening heart， promoting urination and expanding tubes， and the treatment group was additionally treated with Guanxinning Tablets based on treatment of the routine group. The clinical effects and the incidence of adverse reactions were compared between the two groups；the changes in the levels of TGF- β1 and CTGF，Lee's heart failure scores and Modified Early Warning Scale (MEWS) scores were compared before and after treatment between the two groups， and Pearson correlation analysis was performed. Results： The total clinical effective rate was 96.00% in the treatment group and 84.00% in the routine group，the difference being significant (P＜0.05). After treatment，the levels of TGF-β1 and CTGF in the two groups were decreased when compared with those before treatment (P＜0.05)，and the levels of TGF-β1 and CTGF in the treatment group were lower than those in the routine group (P＜0.05). After treatment，Lee's heart failure scores and MEWS scores in the two groups were decreased when compared with those before treatment (P＜0.05)，and Lee's heart failure score and MEWS score in the treatment group were lower than those in the routine group (P＜0.05). Pearson correlation analysis showed that Lee's heart failure score and MEWS score were positively correlated with TGF- β1 and CTGF expression levels. Lee's heart failure score was moderately correlated with TGF- β1 and highly correlated with CTGF，and MEWS score was positively correlated with TGF- β1 and CTGF. The incidence of adverse reactions was 16.00% in the routine group and 6.00% in the treatment group，there being no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion： Guanxinning for patients with DHF of coronary heart disease can enhance the curative effect and improve the condition and prognosis of patients，with high safety.